Analgesic efficacy of sufentanil in dressings after surgical treatment of burn wounds

Kowalski, Grzegorz; Zawadzki, Marcin; Leppert, Wojciech; Szpot, Paweł; Siczek, Marta; Słowiński, Krzysztof; Sobieszczańska, Małgorzata; Gawłowska, Agata; Wieczorowska‐Tobis, Katarzyna

doi:10.1016/j.burns.2020.10.006

Cited by 9 publications

(1 citation statement)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, recent studies have reported several adverse events associated with remifentanil, which may cause hypotension, nausea, vomiting, or bradycardia. Sufentanil is a benzidine derivative that binds to and activates the mu-opioid receptor, thereby producing analgesia [15]. It has been shown that sufentanil is approximately 5 to 10 times as potent as its parent drug, fentanyl.…”

Section: Discussionmentioning

confidence: 99%

Anesthetic effect of sufentanil in patients undergoing cardiovascular surgery

Cheng¹,

Wang²,

Qing³

2023

Trop. J. Pharm Res

View full text Add to dashboard Cite

Purpose: To investigate the effect of sufentanil on anesthesia in patients undergoing cardiovascular surgery. Methods: The subjects comprised a total of 100 patients who were scheduled to undergo cardiovascular surgery in Taikang Tongji (Wuhan) Hospital from January 2021 to December 2021 and met the inclusion criteria. The eligible patients were assigned in a ratio of 1:1 to receive either remifentanil (control group) or sufentanil (study group) during cardiovascular surgery, with 50 patients in each group. The anesthetic effect of remifentanil and sufentanil was compared. Results: Patients treated with sufentanil experienced a faster onset of anesthesia and a shorter time-lapse before extubation, postoperative spontaneous breathing recovery, and postoperative anesthesia recovery when compared with those administered with remifentanil (p < 0.05). Sufentanil provided more potent pain mitigation for patients undergoing cardiovascular surgery than remifentanil, as shown by the lower visual analogue scale (VAS) scores of patients in the study group (p < 0.05). Patients administered with sufentanil showed better levels of mean arterial pressure (MAP) and oxygen saturation (SpO2) than remifentanil, suggesting better hemodynamic benefits provided by sufentanil (p < 0.01). During cardiovascular surgery performed in this study, sufentanil resulted in a higher safety profile by reducing significantly the incidence of adverse reactions (6 %) than remifentanil (30 %) (p < 0.01). Conclusions: Sufentanil exhibits a better anesthetic effect in patients undergoing cardiovascular surgery than remifentanil. It provides potent pain mitigation, effectively ameliorates patients’ hemodynamic status, and reduces the risk of adverse reactions. Future studies with larger sample sizes are required to validate these findings.

show abstract

Section: Discussionmentioning

confidence: 99%